JPH0521888B2 - - Google Patents
Info
- Publication number
- JPH0521888B2 JPH0521888B2 JP62280292A JP28029287A JPH0521888B2 JP H0521888 B2 JPH0521888 B2 JP H0521888B2 JP 62280292 A JP62280292 A JP 62280292A JP 28029287 A JP28029287 A JP 28029287A JP H0521888 B2 JPH0521888 B2 JP H0521888B2
- Authority
- JP
- Japan
- Prior art keywords
- nitroglycerin
- adhesive
- tape
- parts
- polar group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 134
- 239000000006 Nitroglycerin Substances 0.000 claims description 127
- 229960003711 glyceryl trinitrate Drugs 0.000 claims description 127
- 230000001070 adhesive effect Effects 0.000 claims description 73
- 239000000853 adhesive Substances 0.000 claims description 72
- 229920005989 resin Polymers 0.000 claims description 44
- 239000011347 resin Substances 0.000 claims description 44
- -1 glycerin ester Chemical class 0.000 claims description 28
- 239000000463 material Substances 0.000 claims description 21
- 235000019388 lanolin Nutrition 0.000 claims description 19
- 239000004166 Lanolin Substances 0.000 claims description 18
- 229940039717 lanolin Drugs 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims description 15
- 239000010410 layer Substances 0.000 claims description 12
- 230000001681 protective effect Effects 0.000 claims description 12
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 claims description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 11
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 10
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 claims description 10
- 239000003208 petroleum Substances 0.000 claims description 9
- 244000043261 Hevea brasiliensis Species 0.000 claims description 8
- 239000012790 adhesive layer Substances 0.000 claims description 8
- 229920003052 natural elastomer Polymers 0.000 claims description 8
- 229920001194 natural rubber Polymers 0.000 claims description 8
- 125000002723 alicyclic group Chemical group 0.000 claims description 6
- 239000004902 Softening Agent Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 description 31
- 239000002674 ointment Substances 0.000 description 17
- 239000002390 adhesive tape Substances 0.000 description 16
- 239000004698 Polyethylene Substances 0.000 description 15
- 229920000573 polyethylene Polymers 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 206010002383 Angina Pectoris Diseases 0.000 description 11
- 229920001971 elastomer Polymers 0.000 description 11
- 239000005060 rubber Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 10
- 239000000123 paper Substances 0.000 description 10
- 230000003712 anti-aging effect Effects 0.000 description 9
- 238000000576 coating method Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 230000007423 decrease Effects 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000002360 explosive Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 6
- 229910052782 aluminium Inorganic materials 0.000 description 6
- 239000000945 filler Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 206010019233 Headaches Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 229920001296 polysiloxane Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 230000035488 systolic blood pressure Effects 0.000 description 4
- 239000005995 Aluminium silicate Substances 0.000 description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000007757 hot melt coating Methods 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 239000002075 main ingredient Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 229920000098 polyolefin Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 239000003721 gunpowder Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000011088 parchment paper Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 229920006255 plastic film Polymers 0.000 description 2
- 239000002985 plastic film Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 230000036316 preload Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000006190 sub-lingual tablet Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- DMBSFYPSHNCYAR-RJMJUYIDSA-N 1,3-dinitrooxypropan-2-yl nitrate (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O DMBSFYPSHNCYAR-RJMJUYIDSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- BTXXTMOWISPQSJ-UHFFFAOYSA-N 4,4,4-trifluorobutan-2-one Chemical compound CC(=O)CC(F)(F)F BTXXTMOWISPQSJ-UHFFFAOYSA-N 0.000 description 1
- BQACOLQNOUYJCE-FYZZASKESA-N Abietic acid Natural products CC(C)C1=CC2=CC[C@]3(C)[C@](C)(CCC[C@@]3(C)C(=O)O)[C@H]2CC1 BQACOLQNOUYJCE-FYZZASKESA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002388 Angina unstable Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 208000003890 Coronary Vasospasm Diseases 0.000 description 1
- 229910001208 Crucible steel Inorganic materials 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000002586 coronary angiography Methods 0.000 description 1
- 201000011634 coronary artery vasospasm Diseases 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 235000010985 glycerol esters of wood rosin Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012943 hotmelt Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 150000002646 long chain fatty acid esters Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 238000005120 petroleum cracking Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Adhesive Tapes (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62280292A JPS63246326A (ja) | 1987-11-07 | 1987-11-07 | ニトログリセリンを含有する感圧性粘着テープまたはシートの製造方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62280292A JPS63246326A (ja) | 1987-11-07 | 1987-11-07 | ニトログリセリンを含有する感圧性粘着テープまたはシートの製造方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP3684880A Division JPS56133381A (en) | 1980-03-25 | 1980-03-25 | Pressure-sensitive adhesive tape or sheet containing nitroglycerin |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP29999991A Division JPH059115A (ja) | 1991-08-31 | 1991-08-31 | ニトログリセリンを含有する感圧性粘着テープまた はシートの製造方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63246326A JPS63246326A (ja) | 1988-10-13 |
| JPH0521888B2 true JPH0521888B2 (fr) | 1993-03-25 |
Family
ID=17622952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62280292A Granted JPS63246326A (ja) | 1987-11-07 | 1987-11-07 | ニトログリセリンを含有する感圧性粘着テープまたはシートの製造方法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63246326A (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8158145B2 (en) | 2002-02-19 | 2012-04-17 | Hisamitsu Pharmaceutical Co., Inc. | Percutaneous absorption type plaster |
| JP4344175B2 (ja) * | 2003-06-13 | 2009-10-14 | リンテック株式会社 | マトリックス型経皮吸収製剤の製造方法 |
| EP1872784A4 (fr) * | 2005-04-20 | 2012-06-20 | Senju Pharma Co | Preparation medicinale pour une absorption percutanee |
| JP5600799B2 (ja) * | 2013-12-26 | 2014-10-01 | 正則 小林 | 二重瞼形成用テープの製造方法 |
| JP5600798B2 (ja) * | 2013-12-26 | 2014-10-01 | 正則 小林 | 二重瞼形成用テープの製造方法 |
| US11872320B2 (en) | 2021-02-25 | 2024-01-16 | Hisamitsu Pharmaceutical Co., Inc. | Method for treating osteoarthritis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5218812A (en) * | 1975-07-30 | 1977-02-12 | Hifumi Uchimura | Method of preparing antiinflammatory and analgesic plasters |
| JPS552604A (en) * | 1978-06-20 | 1980-01-10 | Sanwa Kagaku Kenkyusho:Kk | Patch agent consisting mainly of nitroglycerin |
| JPS5535633A (en) * | 1978-09-01 | 1980-03-12 | Hisamitsu Pharmaceutical Co | New pasting medicine |
-
1987
- 1987-11-07 JP JP62280292A patent/JPS63246326A/ja active Granted
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5218812A (en) * | 1975-07-30 | 1977-02-12 | Hifumi Uchimura | Method of preparing antiinflammatory and analgesic plasters |
| JPS552604A (en) * | 1978-06-20 | 1980-01-10 | Sanwa Kagaku Kenkyusho:Kk | Patch agent consisting mainly of nitroglycerin |
| JPS5535633A (en) * | 1978-09-01 | 1980-03-12 | Hisamitsu Pharmaceutical Co | New pasting medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS63246326A (ja) | 1988-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS623811B2 (fr) | ||
| EP0062682B1 (fr) | Preparation adhesive pour les maladies du coeur et son procede de preparation | |
| JP2604097B2 (ja) | 皮膚浸透増強剤としてソルビタンエステルを用いた経皮的に薬物を投与するための方法およびシステム | |
| TWI244395B (en) | Pressure-sensitive adhesive transdermal drug delivery system containing low molecular weight drugs which are liquid at room temperatures, and method of providing the same | |
| US5122383A (en) | Sorbitan esters as skin permeation enhancers | |
| JP4943657B2 (ja) | カプサイシンを含むポリシロキサンマトリックスを有する治療パッチ | |
| JPH07138153A (ja) | 有効薬剤の経皮供給 | |
| US5227169A (en) | Sorbitan esters as skin permeation enhancers | |
| JPS61280426A (ja) | 消炎鎮痛用貼付剤 | |
| JPH07501335A (ja) | エストラジオール経皮投与用のアクリル系接着性共重合マトリックスを備えた新規な調合物 | |
| US10532033B2 (en) | Microreservoir system based on polysiloxanes and ambiphilic solvents | |
| JPH0499720A (ja) | 経皮投与用医薬製剤 | |
| JP2001512465A (ja) | 物理的特性の改善されたポリアクリレートマトリックスを有する経皮吸収または局所プラスターシステム | |
| JPS63246325A (ja) | ニトログリセリン貼付剤およびその製造方法 | |
| JPH0521888B2 (fr) | ||
| WO1998051288A1 (fr) | Preparations de patch destinees a etre absorbees par voie percutanee | |
| JP2869167B2 (ja) | 徐放性貼付製剤 | |
| JP4988079B2 (ja) | 経皮吸収型製剤 | |
| JPH0818975B2 (ja) | 疾患治療用貼付剤 | |
| JPH02149514A (ja) | 医薬部材 | |
| HUT59596A (en) | Process for producing transdermal nitroglicerol patches | |
| JPS61112015A (ja) | 医薬製剤 | |
| JPH059115A (ja) | ニトログリセリンを含有する感圧性粘着テープまた はシートの製造方法 | |
| EP0944384B1 (fr) | Systeme d'administration de medicaments transdermiques pour le traitement des maladies du coeur | |
| JPH03246219A (ja) | ニトログリセリンを含有する感圧性粘着テープまたはシート |